MENU
+Compare
SKYE
Stock ticker: NASDAQ
AS OF
Apr 10, 04:59 PM (EDT)
Price
$1.35
Change
-$0.00 (-0.00%)
Capitalization
41.82M

SKYE Skye Bioscience Forecast, Technical & Fundamental Analysis

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California... Show more

SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for SKYE with price predictions
Apr 09, 2025

SKYE's Stochastic Oscillator is sitting in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SKYE's RSI Oscillator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SKYE advanced for three days, in of 236 cases, the price rose further within the following month. The odds of a continued upward trend are .

SKYE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SKYE as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SKYE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SKYE entered a downward trend on April 09, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.614) is normal, around the industry mean (13.320). P/E Ratio (3.566) is within average values for comparable stocks, (62.790). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.760). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (246.160).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SKYE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SKYE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FEREX9.74N/A
N/A
First Eagle Global Real Assets I
PFPPX7.87N/A
N/A
Principal MidCap Growth R3
JGMCX16.94N/A
N/A
Janus Henderson Triton C
MSGZX12.75N/A
N/A
MassMutual Small Cap Gr Eq I
FSSLX9.41N/A
N/A
Fidelity Series Small Cap Core

SKYE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+12.50%
CRBP - SKYE
44%
Loosely correlated
+4.92%
JANX - SKYE
40%
Loosely correlated
+12.75%
VKTX - SKYE
34%
Loosely correlated
+15.49%
PGEN - SKYE
30%
Poorly correlated
+18.80%
XBIT - SKYE
29%
Poorly correlated
+7.03%
More